Virica Biotech Awarded Best Abstract at ISCT 2022-San Francisco Our Data Scientist, Andrea Vervoot and VP of Scientific Operations, JonDavid De Jong represented Virica at International Society of Cell & Gene Therapy (ISCT) 2022 in San Francisco. Andrea Vervoot's abstract presentation on the Bioprocess Modelling of Upstream Viral Vector Production Enhancement won the Best Elevator [...]
For Immediate Release Virica Biotech Announces Collaboration with the Government of Canada to Make Gene Therapies More Accessible and Affordable for Canadians Download full press release here. Ottawa, Canada – May 2, 2022 –Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, [...]
Virica's team have landed at BioProcess International in San Diego! Meet us at the Convention Center and let us talk about how we can increase your viral vector production output. We are located in the Exhibition Hall- Poster Board #29
OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's [...]
Virica is excited to be a part of Advanced Therapies Week, Jan 25th-Jan28th, 2022 at the Miami Convention Center. We are a proud to be a Dynamk Capital portfolio company. Visit us in the Technology of Tomorrow Zone, Booth 11. We look forward to meeting you at Advance Therapies Week! [...]
Please take a moment to watch Virica's Year in Review. We couldn’t have achieved these milestones without you, so thank you.
We now have officially launched our Process Innovation Facility! Take a look at where we enhance the manufacturing of viral medicine.
Watch the grand opening of Virica’s Process Innovation Facility.
OTTAWA – October 4, 2021 – Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth [...]
March 14, 2020—As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved [...]
